Genprex was founded by a team that led Introgen, one of the more notable biotech catastrophes that declared bankruptcy amidst allegations of repeatedly misleading investors. Genprex’s product candidate is based on IP that was abandoned in Introgen’s bankruptcy because it “provide[d] no value to the debtors and [was] of no interest to the potential purchasers”. The product candidate looks to already be in trouble. The company’s Phase II trial has been suspended since April 2016. Genprex’s underwriter, Network 1 Financial, has led or participated in the underwritings of recent disasters such as LongFin, Long Blockchain, Adomani, and CIFS among others. Texas-based Genprex uses a small Boca Raton, Florida-based auditor and has been heavily promoted on penny stock websites and newsletters. We believe Genprex is a zero in the making.